Reata stock jumps 30% as neuromuscular disorder drug meets study endpoint

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 17 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 10%
  • Publisher: 97%

Business Business Headlines News

Business Business Latest News,Business Business Headlines

Reata neuromuscular disorder drug meets study endpoint, stock halted

Reata Pharmaceuticals Inc.

shares surged after hours Monday as the biotech company announced positive results from a clinical trial for a neuromuscular disorder treatment. Reata shares, which had been halted after hours, surged 33% in the extended session, after closing up 5% at $100.59 in Monday trading for a market cap of just over $3 billion.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

why?

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 3. in BUSÄ°NESS

Business Business Latest News, Business Business Headlines